Researchmoz added Most up-to-date research on “Global Ophthalmology Drugs Market to 2022-Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period” to its huge collection of research reports.
Ophthalmology is a therapy area that deals with the diagnosis, treatment and prevention of diseases associated with the eyes and visual system. Most eye disorders occur over a long period of time, and are initially asymptomatic or cause only a slight decrease in vision. However, over time this becomes quite marked. Ophthalmologic disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.
Angiogenesis inhibitors are the most effective and most common therapies used in ophthalmology; this class of compounds has been the most commercially successful in the past decade, with products such as Eylea and Lucentis generating strong annual revenues. Although there are many generics available across the majority of ophthalmology disorders, there are a number of premium products that attract substantial revenues – in particular Eylea, Lucentis, Lumigan and Restasis. The report focuses on five key indications within ophthalmology: glaucoma, age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy and dry eye syndrome. There are currently no therapeutic options available for the treatment of dry AMD, increasing the need for extensive R&D within this area.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=799448
Although there is a high degree of failure and uncertainty within the R&D of ophthalmology drugs, the number of drugs in the pipeline is very high, at 734. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. This shows progression in terms of the variety of different molecules being developed as therapeutic agents within the ophthalmology pipeline. The expected growth of the ophthalmology market over the forecast period is attributed to the approval of new drugs, as well as rising prevalence.
Global revenues for the ophthalmology market are forecast to grow at a compound annual growth rate of 9.48%, from $13.7 billion in 2015 to $26 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
The ophthalmology pipeline is large and diverse, and contains 734 products. How does the composition of the pipeline compare with that of the existing market?
What mechanisms of action and molecule types are most commonly being trialed in pipeline products in the various key indications?
Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
Reasons To Buy
This report will allow you to:
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
Visualize the composition of the ophthalmology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
Analyze the ophthalmology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
Understand the growth in patient epidemiology and market revenues for the ophthalmology market, globally and across the key players and product types
Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various ophthalmology disorders.
Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=799448
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.1.1 Glaucoma 9
2.1.2 Age-Related Macular Degeneration 9
2.1.3 Diabetic Macular Edema 10
2.1.4 Diabetic Retinopathy 10
2.1.5 Dry Eye Syndrome 10
2.2 Symptoms 11
2.3 Etiology and Pathophysiology 13
2.3.1 Etiology 13
2.3.2 Pathophysiology 15
2.4 Co-morbidities and Complications 18
2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 19
2.5.1 Glaucoma 19
2.5.2 Age-Related Macular Degeneration 20
2.5.3 Diabetic Macular Edema 22
2.5.4 Diabetic Retinopathy 22
2.5.5 Dry Eye Syndrome 24
2.6 Treatment 26
3 Key Marketed Products 29
3.1 Overview 29
3.2 Lucentis (ranibizumab) 29
3.3 Eylea (aflibercept) 30
3.4 Avastin (bevacizumab) 31
3.5 Restasis (cyclosporine) 32
3.6 Alphagan (brimonidine tartrate) 34
3.7 Lumigan (bimatoprost) 35
3.8 Xalatan (latanoprost) 36
4 Pipeline Landscape Assessment 38
4.1 Overview 38
4.2 Pipeline Development Landscape 38
4.3 Mechanisms of Action in the Pipeline 41
4.4 Clinical Trials 43
4.4.1 Failure Rate 43
4.4.2 Clinical Trial Duration 47
4.4.3 Clinical Trial Size 51
4.4.4 Aggregate Clinical Program Size 55
4.4.5 Conclusion 59
5 Multi-Scenario Market Forecast to 2022 60
5.1 Overall Market Size 60
5.2 Generic Penetration 61
5.3 Revenue Forecast by Molecular Target 62
5.3.1 Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors) 62
5.3.2 Antihistamines (H1 Receptor) 63
5.3.3 Anti-inflammatories (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor) 64
5.3.4 IOP-Lowering (Prostaglandins/Beta Blockers/Rho Kinase Signaling Pathway) 65
5.3.5 Assessment of Key Pipeline Products 65